Effect of resveratrol on cognitive functions and inflammation in a population of older adults with type 2 diabetes mellitus

Effect of oral administration of resveratrol on markers of oxidative stress, inflammation and cognitive functions in a population of older adults with type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN15172592

Enrollment

120

Registered

2021-09-27

Start date

2020-05-16

Completion date

Unknown

Last updated

2024-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus Nutritional, Metabolic, Endocrine Type 2 diabetes mellitus

Interventions

The sample will be randomly divided into three groups: 1. Experimental A will receive a capsule with 500 mg of resveratrol (RV) daily for 12 months 2. Experimental B will receive two capsules with 500

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Clinical diagnosis of diabetes mellitus type 2 2. People over 60 years of age 3. Residence in Mexico City 4. Either sex

Exclusion criteria

Exclusion criteria: 1. Smoking or alcoholism 2. People who have taken antioxidant supplements or anti-inflammatories in the last 6 months 3. Without replacement hormones, in the case of women

Design outcomes

Primary

Measure	Time frame
Cognitive functions that are measured at the beginning and at 12 months by: 1. Rey's auditory-verbal learning test 2. The digit and symbol string test 3. The stroke test	—

Secondary

Measure	Time frame
1. Markers of oxidative stress measured at the beginning of the study and at 12 months using: 1.1 Isoprostanes, by enzyme-linked immunosorbent assay (ELISA) 1.2 DNA damage by alkaline electrophoresis 1.3 Total antioxidant activity, by spectrophotometric technique using a commercial kit from Randox Laboratories Ltd. 1.4 The antioxidant capacity of the enzymes superoxide dismutase and glutathione peroxidase, by spectrophotometric technique using a commercial kit from Randox Laboratories Ltd. 2. Markers of chronic inflammation at baseline and at 12 months measured using: 2.1 C-reactive protein (CRP), by nephelometry using a commercial kit from Randox Laboratories Ltd. 2.2 IL1, IL6, TNF-a and IL10, will be performed by flow cytometry with a commercial BD kit. 3. Degree of control measured at the beginning and at 12 months through levels of: 3.1 glucose, HBA1c, lipid profile (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides), kidney profile (uric acid, creatinine, urea) that will be carried out in an automated equipment (Selectra Junior), and commercial kits will be used (Randox Laboratories Ltd.). 3.2 Blood pressure, measured by trained nursing personnel.	—

Measure

Time frame

1. Markers of oxidative stress measured at the beginning of the study and at 12 months using: 1.1 Isoprostanes, by enzyme-linked immunosorbent assay (ELISA) 1.2 DNA damage by alkaline electrophoresis 1.3 Total antioxidant activity, by spectrophotometric technique using a commercial kit from Randox Laboratories Ltd. 1.4 The antioxidant capacity of the enzymes superoxide dismutase and glutathione peroxidase, by spectrophotometric technique using a commercial kit from Randox Laboratories Ltd. 2. Markers of chronic inflammation at baseline and at 12 months measured using: 2.1 C-reactive protein (CRP), by nephelometry using a commercial kit from Randox Laboratories Ltd. 2.2 IL1, IL6, TNF-a and IL10, will be performed by flow cytometry with a commercial BD kit. 3. Degree of control measured at the beginning and at 12 months through levels of: 3.1 glucose, HBA1c, lipid profile (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides), kidney profile (uric acid, creatinine, urea) that will be carried out in an automated equipment (Selectra Junior), and commercial kits will be used (Randox Laboratories Ltd.). 3.2 Blood pressure, measured by trained nursing personnel.

—

Countries

Guatemala, Mexico

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026